Astrocytes study identifies a new therapeutic target for Alzheimer's disease
Worldwide, at least 50 million people are believed to be living with a form of dementia. Alzheimer's disease is the most ...
Pharmaceutical Technology3d
Glucokinase drugs in development, 2024
GlobalData’s report assesses the drugs in the Glucokinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
University of Sheffield1y
Neuroscience Institute
Research from the Neuroscience Institute identifies the impact of a reduction in astrocytes in the hexokinase 1 (HK1) enzyme in Alzheimer’s disease, paving a new pathway for potential treatments.
eLife8d
The deubiquitinase Ubp3/Usp10 constrains glucose-mediated mitochondrial repression via phosphate budgeting
A primary constraint for mitochondrial repression is access to cytosolic inorganic phosphate, which is determined by the glycolytic flux rate.
Medscape8d
Sugar, Uric Acid, and the Etiology of Diabetes and Obesity
Richard J. Johnson; Takahiko Nakagawa; L. Gabriela Sanchez-Lozada; Mohamed Shafiu; Shikha Sundaram; Myphuong Le; Takuji Ishimoto; Yuri Y. Sautin; Miguel A. Lanaspa ...
Vidac Pharma Holding PLC: U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class ...